CuraScientific (CuraScientific) EBIT : $33.89 Mil (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is CuraScientific EBIT?

CuraScientific's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-5.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $33.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CuraScientific's annualized ROC % for the quarter that ended in Sep. 2023 was -13.46%. CuraScientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -9,153.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CuraScientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 2,340.33%.

CuraScientific EBIT Historical Data

The historical data trend for CuraScientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific EBIT Chart

CuraScientific Annual Data

Trend

Dec20

Dec21

Dec22

EBIT

-4.50

-4.71

-4.05

CuraScientific Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial							0.59	-1.65	-0.21	41.31	-5.56

Competitive Comparison of CuraScientific's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CuraScientific's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CuraScientific's EV-to-EBIT falls into.

CuraScientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.89 Mil.

CuraScientific (OTCPK:CSTF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CuraScientific's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-3.544 * ( 1 - 0% )	/	( (27.135	+	25.512)	/ 2 )
=	-3.544	/	26.3235
=	-13.46 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.476	-	1.003	-	( 0.282	-	max(0, 27.014	-	0.352	+	0.282	))
=	27.135

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.617	-	1.082	-	( 0.041	-	max(0, 26.057	-	1.08	+	0.041	))
=	25.512

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

CuraScientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-22.244	/	( ( (0.199 + max(-26.454, 0))	+	(0.287 + max(-24.377, 0)) )	/	2 )
=	-22.244	/	( ( 0.199	+	0.287 )	/	2 )
=	-22.244	/	0.243
=	-9,153.91 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.052	+	0.018)	-	(1.003	+	0	+	25.521)
=	-26.454

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.002	+	0.045	+	0.992)	-	(1.082	+	0	+	24.334)
=	-24.377

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CuraScientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	33.888	/	1.448
	=	2,340.33 %

CuraScientific EBIT Related Terms

Thank you for viewing the detailed overview of CuraScientific's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236

Website

https://www.curascientificcorp.com

CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.

Executives

Paul Quentin Goyette	director	2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed	director, officer: Chief Executive Officer	333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen	director	C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette	director	13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez	director, officer: Chief Executive Officer	15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson	director, officer: Chief Operating Officer	19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020